Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454896 · ClinicalTrials.gov registry record · Phase 3
A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 739
- Enrollment target
NCT00454896 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 739 participants.
The verdict
NCT00454896, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 739 participants
- Enrollment target
Study Summary
The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome.
Interventions
- DRUG placebo
- DRUG VESIcare®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 739 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454896
The ClinicalTrials.gov registry entry for NCT00454896 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 739 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00454896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00454896 about?
NCT00454896 is a clinical study titled "A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)". The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome.
What is the current status of trial NCT00454896?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 739 participants. The study started on 2004-05. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00454896?
The interventions under investigation include: placebo (DRUG), VESIcare® (DRUG).
Who is sponsoring clinical trial NCT00454896?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.